BioElectronics
Market Cap
US$14.0m
Last Updated
2020/08/14 00:38 UTC
Data Sources
Company Financials
Executive Summary
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide.
Risk Analysis
+ 1 more risk
Snowflake Analysis
Weak fundamentals or lack of information.
Share Price & News
How has BioElectronics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIEL has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0%
BIEL
0.8%
US Medical Equipment
0.5%
US Market
1 Year Return
-14.3%
BIEL
17.2%
US Medical Equipment
18.7%
US Market
Return vs Industry: BIEL underperformed the US Medical Equipment industry which returned 18% over the past year.
Return vs Market: BIEL underperformed the US Market which returned 20.1% over the past year.
Shareholder returns
| BIEL | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 0.8% | 0.5% |
| 30 Day | -14.3% | 5.9% | 4.9% |
| 90 Day | 0% | 14.4% | 19.8% |
| 1 Year | -14.3%-14.3% | 18.1%17.2% | 21.2%18.7% |
| 3 Year | 0%0% | 76.5%71.8% | 46.2%36.8% |
| 5 Year | -25.0%-25.0% | 130.3%112.4% | 85.3%65.1% |
Price Volatility Vs. Market
How volatile is BioElectronics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is BioElectronics undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether BioElectronics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioElectronics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at our analysis of BIEL's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through BioElectronics regulatory filings here.
- Explore potentially undervalued companies in the Healthcare industry.
Future Growth
How is BioElectronics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
28.7%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioElectronics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Take a look at our analysis of BIEL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access BioElectronics's filings and announcementshere.
- Explore growth companies in the Healthcare industry.
Past Performance
How has BioElectronics performed over the past 5 years?
-25.6%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: BIEL is currently unprofitable.
Growing Profit Margin: BIEL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BIEL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BIEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIEL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.2%).
Return on Equity
High ROE: BIEL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is BioElectronics's financial position?
Financial Position Analysis
Short Term Liabilities: BIEL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BIEL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BIEL has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BIEL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if BIEL has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BIEL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is BioElectronics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIEL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIEL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.8yrs
Average board tenure
CEO
Kelly Whelan
0.83
Tenure
Ms. Kelly A. Whelan serves as Executive Director at BioElectronics Corporation since November 2019. She has been Chief Executive Officer and President of BioElectronics Corporation since October 2019. She ...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 0.83yr | no data | no data | |
| VP of Sales & Marketing and Executive Director | 0.75yr | no data | no data | |
| Director of Clinical Research & Member of Medical Advisory Board | no data | no data | no data | |
| Chairman of Medical Advisory Board | no data | no data | no data | |
| Independent Chairman | 0.17yr | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
0.8yrs
Average Tenure
Experienced Board: BIEL's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.
Top Shareholders
Company Information
BioElectronics Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: BioElectronics Corporation
- Ticker: BIEL
- Exchange: OTCPK
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$14.023m
- Shares outstanding: 23.37b
- Website: https://www.bielcorp.com
Location
- BioElectronics Corporation
- 4539 Metropolitan Court
- Frederick
- Maryland
- 21704
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BIEL | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Apr 2004 |
Biography
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/14 00:38 |
| End of Day Share Price | 2020/08/13 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.